Tuesday, August 25, 2020 3:29:05 PM
ALERT! TEVA Charged For Generic Drugs Price-Fixing Probe
U.S. Poised to Charge Teva in Generic Drugs Price-Fixing Probe
Aug. 25, 2020, 2:16 PM
U.S. prosecutors are preparing to charge Teva Pharmaceutical Industries Ltd. with conspiring with competitors to raise prices for generic drugs, according to a person familiar with the matter.
The Justice Department is planning to charge Teva as soon as Tuesday after the company rebuffed a settlement that would have required paying a criminal penalty and admitting wrongdoing, said the person, who declined to be named because the matter is confidential.
A spokesperson for Teva, which is based in Israel, declined to comment.
https://news.bloomberglaw.com/pharma-and-life-sciences/u-s-poised-to-charge-teva-in-generic-drugs-price-fixing-probe
Recently
Drug firm bets it won't be charged
In the coming days, the Justice Department will decide whether to file criminal charges against one of the world's largest pharmaceutical companies suspected of colluding with rivals to inflate the prices of widely used drugs.
The company, Teva Pharmaceutical Industries, is betting that in the middle of a deadly pandemic, the Trump administration won't dare to come down hard on the largest supplier of generic drugs in the United States.
It is a high-stakes gamble that could affect millions of Americans who rely on Teva's dozens of inexpensive generic drugs, as well as its brand-name products like Copaxone, for multiple sclerosis, and Ajovy, for migraines. Teva officials say criminal charges could cripple the Israeli company and potentially leave it unable to sell drugs to federal programs like Medicare.
For years, the Justice Department and state prosecutors have been investigating what they describe as a conspiracy by pharmaceutical companies to increase the prices of popular drugs. The department has already extracted guilty pleas and $224 million in penalties from four other drug companies.
Lawyers for Teva, which prosecutors believe was deeply involved in the conspiracy, until recently had been holding settlement negotiations with officials in the Justice Department's antitrust division. But in April, the company all but walked away from the talks, according to people on both sides of the discussions.
U.S. Poised to Charge Teva in Generic Drugs Price-Fixing Probe
Aug. 25, 2020, 2:16 PM
U.S. prosecutors are preparing to charge Teva Pharmaceutical Industries Ltd. with conspiring with competitors to raise prices for generic drugs, according to a person familiar with the matter.
The Justice Department is planning to charge Teva as soon as Tuesday after the company rebuffed a settlement that would have required paying a criminal penalty and admitting wrongdoing, said the person, who declined to be named because the matter is confidential.
A spokesperson for Teva, which is based in Israel, declined to comment.
https://news.bloomberglaw.com/pharma-and-life-sciences/u-s-poised-to-charge-teva-in-generic-drugs-price-fixing-probe
Recently
Drug firm bets it won't be charged
In the coming days, the Justice Department will decide whether to file criminal charges against one of the world's largest pharmaceutical companies suspected of colluding with rivals to inflate the prices of widely used drugs.
The company, Teva Pharmaceutical Industries, is betting that in the middle of a deadly pandemic, the Trump administration won't dare to come down hard on the largest supplier of generic drugs in the United States.
It is a high-stakes gamble that could affect millions of Americans who rely on Teva's dozens of inexpensive generic drugs, as well as its brand-name products like Copaxone, for multiple sclerosis, and Ajovy, for migraines. Teva officials say criminal charges could cripple the Israeli company and potentially leave it unable to sell drugs to federal programs like Medicare.
For years, the Justice Department and state prosecutors have been investigating what they describe as a conspiracy by pharmaceutical companies to increase the prices of popular drugs. The department has already extracted guilty pleas and $224 million in penalties from four other drug companies.
Lawyers for Teva, which prosecutors believe was deeply involved in the conspiracy, until recently had been holding settlement negotiations with officials in the Justice Department's antitrust division. But in April, the company all but walked away from the talks, according to people on both sides of the discussions.
Recent TEVA News
- The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults • GlobeNewswire Inc. • 05/21/2026 04:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:02:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:00:48 PM
- Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution • GlobeNewswire Inc. • 05/18/2026 12:30:00 PM
- Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact • GlobeNewswire Inc. • 05/18/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 08:02:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 07:59:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 08:03:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 08:01:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/05/2026 08:00:07 PM
- Teva to Present at the BofA Securities Health Care Conference • GlobeNewswire Inc. • 05/04/2026 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:02:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:00:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/04/2026 12:12:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/30/2026 08:40:45 PM
- Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 08:06:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:00:20 AM
- Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy • GlobeNewswire Inc. • 04/29/2026 10:30:00 AM
- Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:43:03 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:41:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:38:29 PM
